Evidence map›Paper›PMID 36817923›Full record

SynthesisFrontiers in public health2023

An innovative framework to determine the implementation level of personalized medicine: A systematic review.

Lorena Aguilera-Cobos, Patricia García-Sanz, María Piedad Rosario-Lozano, M Gonzalo Claros, Juan Antonio Blasco-Amaro

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lorena Aguilera-CobosHealth Technology Assessment Area-AETSA, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
Patricia García-SanzHealth Technology Assessment Area-AETSA, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
María Piedad Rosario-LozanoHealth Technology Assessment Area-AETSA, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
M Gonzalo ClarosDepartment of Molecular Biology and Biochemistry, Universidad de Málaga, Málaga, Spain.
Juan Antonio Blasco-AmaroHealth Technology Assessment Area-AETSA, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
Fundación Progreso y Salud · ESCentre for Biomedical Network Research on Rare Diseases · ESUniversidad de Málaga · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Personalized medicine (PM) is now the new frontier in patient care. The application of this new paradigm extends to various pathologies and different patient care phases, such as diagnosis and treatment. Translating biotechnological advances to clinical routine means adapting health services at all levels is necessary. Purpose: This article aims to identify the elements for devising a framework that will allow the level of PM implementation in the country under study to be quantitatively and qualitatively assessed and that can be used as a guideline for future implementation plans. Methods: A systematic review was conducted per Results: 19 full-text studies that met the inclusion criteria were peer-selected in the systematic review. From all the studies that were included, 37 elements-encompassed in 11 domains-were extracted for determining the degree of PM implementation. These domains and their constituent elements comprise the qualitative and quantitative assessment framework presented herein. Each of the elements can be assessed individually. On the other hand, the domains were standardized to all have the same weight in an overall assessment. Conclusions: A framework has been developed that takes a multi-factorial approach to determine the degree of implementation of PM at the national level. This framework could also be used to rank countries and their implementation strategies according to the score they receive in the application of the latter. It could also be used as a guide for developing future national PM implementation strategies. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022338611, Identifier: CRD42022338611.

Indexed as

BiotechnologyPrecision MedicineHumansPeer Groupframeworkhealth policyhealth systemimplementationpersonalized medicine (PM)

Identifiers

PMID36817923
PMCPMC9936069
OpenAlexW4319161373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.